Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04124341 · ClinicalTrials.gov registry record · NA

PCS in Severe Treatment Resistant Depression

A NA study of Treatment-Resistant Depression, sponsored by University of Minnesota.

Recruiting
Registry status
NA
Development phase
15
Enrollment target
1
Study location

NCT04124341: Recruiting NA study of Treatment-Resistant Depression, sponsored by University of Minnesota.

NCT04124341 is a NA study of Treatment-Resistant Depression that is actively recruiting participants, run by University of Minnesota. The registered enrollment target is 15 participants, below the 374-participant average among 54 other Treatment-Resistant Depression trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04124341, a NA study of Treatment-Resistant Depression, is actively recruiting participants, sponsored by University of Minnesota.

RECRUITING
Registry status
NA
Development phase
15 participants
Enrollment target
1
Study location

Study Summary

This research study is designed to test if electrical stimulation of the surface of the brain in the frontal region will help treat depressive symptoms. Participants receive intermittent electrical stimulation to the brain, which involves surgically placing electric leads in between the tough fibrous membrane covering the surface of the brain and the surface of the brain itself. This type of stimulation is referred to as bilateral subdural prefrontal cortical stimulation (PCS) because it will specifically target the outer layer of the brain at the midline, right behind the forehead. It uses a pacemaker-like device, the Proclaim Elite SCS System (non-rechargeable) or the Eterna SCS System (rechargeable), both by Abbott Laboratories for stimulation. Although the U.S. Food and Drug Administration (FDA) has approved the Proclaim Elite SCS system for brain stimulation for patients with chronic pain and muscular diseases, such as Parkinson's, its use is still investigational, and the surgery is still experimental for patients who have depression.

Primary Outcome

Determine clinical change in depressive symptoms over first year of treatment

Interventions

  • DEVICE Prefrontal Cortical Stimulation (PCS)

Study Locations (1)

Minnesota

  • University of Minnesota - Minneapolis

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2021-09-29
Est. Completion 2032-12-31
Phase NA
University of Minnesota

966 total trials

What NCT04124341 shows while recruiting

NCT04124341 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 374-participant average among 54 other Treatment-Resistant Depression trials with a reported enrollment target (96% lower).

The record links to 1 condition, with Treatment-Resistant Depression appearing as the primary indexed condition, and to 1 intervention - of which Prefrontal Cortical Stimulation (PCS) is the first listed.

NCT04124341 reports a single indexed study location in Minnesota.

Frequently Asked Questions

What is clinical trial NCT04124341 about?

NCT04124341 is a clinical study titled "PCS in Severe Treatment Resistant Depression". This research study is designed to test if electrical stimulation of the surface of the brain in the frontal region will help treat depressive symptoms. Participants receive intermittent electrical stimulation to the brain, which involves surgically placing electric leads in between the tough fibrou...

What is the current status of trial NCT04124341?

This trial is currently recruiting. It is a NA study. The enrollment target is 15 participants. The study started on 2021-09-29. Estimated completion is 2032-12-31.

What conditions does trial NCT04124341 study?

This clinical trial studies the following conditions: Treatment-Resistant Depression.

What interventions are being tested in trial NCT04124341?

The interventions under investigation include: Prefrontal Cortical Stimulation (PCS) (DEVICE).

Who is sponsoring clinical trial NCT04124341?

This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04124341 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Treatment-Resistant Depression

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04124341's enrollment target sits among peer trials

15 45th of 54 higher than 9 of 54 other Treatment-Resistant Depression trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Treatment-Resistant Depression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01889381 · 15 participants · Phase 2

    Human Craniomaxillofacial Allotransplantation

  • NCT02530073 · 15 participants · NA

    Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH

  • NCT02535936 · 15 participants · NA

    Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy

  • NCT02918474 · 15 participants · NA

    Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04124341, the US trial registry maintained by the National Library of Medicine. NCT04124341 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.